Wu Yifang resigned as Shanghai Fosun Pharmaceutical's (HKG:2196, SHA:600196) chairman due to the adjustment of work arrangements effective Tuesday, a same-day Hong Kong bourse filing said.
Wu has also been redesignated from an executive director to a non-executive director.
Co-Chair Wang Kexin also stepped down the same day due to work adjustment, but will continue serving as an executive director.
The pharmaceutical firm, on the same day, named Chen Yuqing as chairman, after he was redesignated from a non-executive director to an executive director; Guan Xiaohui as co-chairman; and Wen Deyong as vice chairman
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.